SCHEMBL792499

SCHEMBL792499

CC(=O)c1ccc2c(C)c(C)n(COc3ccccc3C)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR2F2 P24468 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
CETP P11597 1/20 0.39
CEPT1 Q9Y6K0 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
THRB P10828 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAOB P27338 1/20 0.38
HPGD P15428 2/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792576 0.76 MAPT (0.48) ALDH1A1HPGDKDM4EMEN1CYP1A2
SCHEMBL8386913 0.76 HDAC3 (0.56) TDP1HDAC3HDAC1HDAC2HDAC10
SCHEMBL792096 0.75 HDAC3 (0.39) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL792363 0.74 ALDH1A1 (0.52) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL5330203 0.66 L3MBTL1 (0.74) RXRARXRBRXRGTDP1L3MBTL1
SCHEMBL21135536 0.66 ALDH1A1 (0.59) TDP1ALDH1A1HPGDLMNAKDM4E
SCHEMBL29808829 0.66 ALDH1A1 (0.59) TDP1ALDH1A1HPGDLMNAKDM4E
SCHEMBL14211078 0.65 PPARG (0.55) TDP1L3MBTL1HDAC3HDAC1HDAC2
SCHEMBL12398081 0.65 TDP1 (0.63) TDP1L3MBTL1HDAC3HDAC1HDAC2
SCHEMBL9655200 0.65 CREBBP (0.44) RXRARXRBRXRGTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 NR2F2 804/4885RXRA 3646/4885RXRB 3821/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 NR2F2 804/4885RXRA 3646/4885RXRB 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.